Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · IEX Real-Time Price · USD
0.565
-0.003 (-0.48%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021
Revenue
00.050.45
Revenue Growth (YoY)
--89.98%-
Cost of Revenue
00.010.09
Gross Profit
00.030.36
Selling, General & Admin
15.9815.96.16
Research & Development
13.017.263.8
Other Operating Expenses
000.88
Operating Expenses
28.9923.1610.84
Operating Income
-28.99-23.13-10.48
Interest Expense / Income
1.070.160.61
Other Expense / Income
-0.862.13-0.17
Pretax Income
-29.2-25.42-10.92
Income Tax
0.020.010.01
Net Income
-29.22-25.43-10.93
Shares Outstanding (Basic)
17920
Shares Outstanding (Diluted)
17920
Shares Change
98.55%-56.93%-
EPS (Basic)
-1.73-2.99-0.55
EPS (Diluted)
-1.73-2.99-0.55
Free Cash Flow
-27.57-13.64-7.98
Free Cash Flow Per Share
-1.63-1.60-0.40
Gross Margin
-68.89%79.06%
Operating Margin
--51395.56%-2334.52%
Profit Margin
--56504.44%-2434.97%
Free Cash Flow Margin
--30315.56%-1777.28%
EBITDA
-26.88-25.01-10.15
EBITDA Margin
--55566.67%-2261.02%
Depreciation & Amortization
1.260.250.16
EBIT
-28.13-25.26-10.31
EBIT Margin
--56128.89%-2295.77%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).